These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 9800200)
1. [Olanzapine: preclinical pharmacology and recent findings]. Moore N Nihon Shinkei Seishin Yakurigaku Zasshi; 1998 Jun; 18(3):91-5. PubMed ID: 9800200 [No Abstract] [Full Text] [Related]
2. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. Moore NA; Leander JD; Benvenga MJ; Gleason SD; Shannon H J Clin Psychiatry; 1997; 58 Suppl 10():37-44. PubMed ID: 9265915 [TBL] [Abstract][Full Text] [Related]
3. Olanzapine: a basic science update. Bymaster F; Perry KW; Nelson DL; Wong DT; Rasmussen K; Moore NA; Calligaro DO Br J Psychiatry Suppl; 1999; (37):36-40. PubMed ID: 10211140 [TBL] [Abstract][Full Text] [Related]
4. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Bymaster FP; Calligaro DO; Falcone JF; Marsh RD; Moore NA; Tye NC; Seeman P; Wong DT Neuropsychopharmacology; 1996 Feb; 14(2):87-96. PubMed ID: 8822531 [TBL] [Abstract][Full Text] [Related]
5. The in vivo effects of olanzapine and other antipsychotic agents on receptor occupancy and antagonism of dopamine D1, D2, D3, 5HT2A and muscarinic receptors. Zhang W; Bymaster FP Psychopharmacology (Berl); 1999 Jan; 141(3):267-78. PubMed ID: 10027508 [TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. Bymaster FP; Rasmussen K; Calligaro DO; Nelson DL; DeLapp NW; Wong DT; Moore NA J Clin Psychiatry; 1997; 58 Suppl 10():28-36. PubMed ID: 9265914 [TBL] [Abstract][Full Text] [Related]
7. Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. Kusumi I; Takahashi Y; Suzuki K; Kameda K; Koyama T J Neural Transm (Vienna); 2000; 107(3):295-302. PubMed ID: 10821438 [TBL] [Abstract][Full Text] [Related]
8. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. Moore NA; Tye NC; Axton MS; Risius FC J Pharmacol Exp Ther; 1992 Aug; 262(2):545-51. PubMed ID: 1354253 [TBL] [Abstract][Full Text] [Related]
9. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Schmidt AW; Lebel LA; Howard HR; Zorn SH Eur J Pharmacol; 2001 Aug; 425(3):197-201. PubMed ID: 11513838 [TBL] [Abstract][Full Text] [Related]
10. Influence of olanzapine on cognitive functions and catalepsy in rats after single and chronic administration. Nowakowska E; Chodera A; Kus K Pol J Pharmacol; 1999; 51(4):295-300. PubMed ID: 10540960 [TBL] [Abstract][Full Text] [Related]
11. Olanzapine: preclinical pharmacology and recent findings. Moore NA Br J Psychiatry Suppl; 1999; (37):41-4. PubMed ID: 10211141 [TBL] [Abstract][Full Text] [Related]
12. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Raedler TJ; Knable MB; Jones DW; Lafargue T; Urbina RA; Egan MF; Pickar D; Weinberger DR Neuropsychopharmacology; 2000 Jul; 23(1):56-68. PubMed ID: 10869886 [TBL] [Abstract][Full Text] [Related]
13. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Kapur S; Zipursky RB; Remington G Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565 [TBL] [Abstract][Full Text] [Related]
14. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. Lavalaye J; Booij J; Linszen DH; Reneman L; van Royen EA Psychopharmacology (Berl); 2001 Jun; 156(1):53-7. PubMed ID: 11465633 [TBL] [Abstract][Full Text] [Related]
15. Discriminative stimulus control with olanzapine: generalization to the atypical antipsychotic clozapine. Porter JH; Strong SE Psychopharmacology (Berl); 1996 Nov; 128(2):216-9. PubMed ID: 8956383 [TBL] [Abstract][Full Text] [Related]
16. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Tarazi FI; Zhang K; Baldessarini RJ Psychopharmacology (Berl); 2002 May; 161(3):263-70. PubMed ID: 12021829 [TBL] [Abstract][Full Text] [Related]
17. Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium. Bymaster FP; Falcone JF Eur J Pharmacol; 2000 Mar; 390(3):245-8. PubMed ID: 10708730 [TBL] [Abstract][Full Text] [Related]
18. Olanzapine attenuates the reinforcing effects of cocaine. Meil WM; Schechter MD Eur J Pharmacol; 1997 Dec; 340(1):17-26. PubMed ID: 9527502 [TBL] [Abstract][Full Text] [Related]
19. Behavioral characteristics of olanzapine: an atypical neuroleptic. Fu Y; Zhu ZT; Chen LJ; Yu LP; Jin GZ Acta Pharmacol Sin; 2000 Apr; 21(4):329-34. PubMed ID: 11324461 [TBL] [Abstract][Full Text] [Related]
20. D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET. Remington G; Kapur S J Clin Psychiatry; 1999; 60 Suppl 10():15-9. PubMed ID: 10340683 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]